Side Effects Dampen Neurologists' Enthusiasm For Novel MS Drugs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With nearly a dozen new multiple sclerosis drugs in some phase of mid- to late-stage development – from the first oral options to infrequently administered biologics – the treatment paradigm for the debilitating disease appears on the cusp of significant change.
You may also be interested in...
Biogen Idec To Pursue Disability Label Claim For BG-12 Despite Missed Endpoint
Relapse reduction in multiple sclerosis was robust, though lower than in the first Phase III trial, but the drug missed the statistical mark on disability progression.
Sanofi's Oral Aubagio Jostles For Position In Multiple Sclerosis Market
FDA accepts filing for teriflunomide, but concerns about pregnancy risk in a young patient population and questions about comparative efficacy could limit market potential.
Innate Therapeutics Wins $550K From Fast Forward For Therapy Aimed At Progressive MS
Validation from the venture philanthropy garnered the New Zealand biotech another NZD600,000 from the NZ government.